...
首页> 外文期刊>British Journal of Cancer >Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma
【24h】

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma

机译:切除食管腺癌的免疫组化预后生物标志物的系统评价和荟萃分析

获取原文

摘要

Background: Oesophageal adenocarcinoma (OAC) is one of the fastest rising malignancies with continued poor prognosis. Many studies have proposed novel biomarkers but, to date, no immunohistochemical markers of survival after oesophageal resection have entered clinical practice. Here, we systematically review and meta-analyse the published literature, to identify potential biomarkers. Methods: Relevant articles were identified via Ovid medline 1946–2013. For inclusion, studies had to conform to REporting recommendations for tumor MARKer (REMARK) prognostic study criteria. The primary end-point was a pooled hazard ratio (HR) and variance, summarising the effect of marker expression on prognosis. Results: A total of 3059 articles were identified. After exclusion of irrelevant titles and abstracts, 214 articles were reviewed in full. Nine molecules had been examined in more than one study (CD3, CD8, COX-2, EGFR, HER2, Ki67, LgR5, p53 and VEGF) and were meta-analysed. Markers with largest survival effects were COX-2 (HR=2.47, confidence interval (CI)=1.15–3.79), CD3 (HR=0.51, 95% CI=0.32–0.70), CD8 (HR=0.55, CI=0.31–0.80) and EGFR (HR=1.65, 95% CI=1.14–2.16). Discussion: Current methods have not delivered clinically useful molecular prognostic biomarkers in OAC. We have highlighted the paucity of good-quality robust studies in this field. A genome-to-protein approach would be better suited for the development and subsequent validation of biomarkers. Large collaborative projects with standardised methodology will be required to generate clinically useful biomarkers.
机译:背景:食道腺癌(OAC)是上升最快的恶性肿瘤之一,预后持续不佳。许多研究提出了新的生物标志物,但迄今为止,尚无食管切除术后生存的免疫组织化学标志物进入临床实践。在这里,我们系统地审查和荟萃分析已发表的文献,以识别潜在的生物标志物。方法:通过Ovid medline 1946–2013确定相关文章。为了纳入,研究必须符合针对肿瘤标志物(REMARK)预后研究标准的报告建议。主要终点是合并的危险比(HR)和差异,总结了标记物表达对预后的影响。结果:共鉴定到3059篇文章。在排除无关的标题和摘要之后,对214条文章进行了全面审查。在一项以上的研究中检查了九种分子(CD3,CD8,COX-2,EGFR,HER2,Ki67,LgR5,p53和VEGF)并进行了荟萃分析。存活率最高的标记是COX-2(HR = 2.47,置信区间(CI)= 1.15–3.79),CD3(HR = 0.51,95%CI = 0.32–0.70),CD8(HR = 0.55,CI = 0.31– 0.80)和EGFR(HR = 1.65,95%CI = 1.14–2.16)。讨论:当前的方法尚未在OAC中提供临床上有用的分子预后生物标志物。我们强调了该领域缺乏高质量的稳健研究。基因组到蛋白质的方法将更适合于生物标志物的开发和后续验证。将需要采用标准化方法的大型协作项目来产生临床上有用的生物标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号